(82) demonstrated a liposome-based nano-vaccine carrier that uses ganglioside as a targeting ligand to deliver tumor antigens to human CD169/Siglec-1+ antigen-presenting cells. This evidence concerns the gene SIGLEC1 and neoplasm.